Tim Anderson
Stock Analyst at B of A Securities
(4.42)
# 319
Out of 4,996 analysts
43
Total ratings
72%
Success rate
14.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMGN Amgen | Maintains: Underperform | $261 → $272 | $272.98 | -0.36% | 6 | Sep 26, 2025 | |
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $38.21 | +127.69% | 1 | Aug 28, 2025 | |
| MTSR Metsera | Maintains: Buy | $45 → $50 | $52.25 | -4.31% | 2 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $13.23 | +88.96% | 3 | Aug 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $27 → $28 | $23.76 | +17.85% | 2 | Aug 6, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $161 → $175 | $179.71 | -2.62% | 6 | Jul 17, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $204 | $220.61 | -7.53% | 7 | Apr 28, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $575 → $547 | $563.90 | -3.00% | 2 | Apr 17, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $112.10 | +12.40% | 3 | Mar 5, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $24.49 | +38.83% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $112 | $78.56 | +42.57% | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $44.12 | +42.79% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $137.37 | +29.58% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $724.54 | +37.60% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $123.65 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $73.76 | - | 1 | Sep 22, 2017 |
Amgen
Sep 26, 2025
Maintains: Underperform
Price Target: $261 → $272
Current: $272.98
Upside: -0.36%
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $38.21
Upside: +127.69%
Metsera
Aug 28, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $52.25
Upside: -4.31%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $13.23
Upside: +88.96%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $27 → $28
Current: $23.76
Upside: +17.85%
Johnson & Johnson
Jul 17, 2025
Maintains: Neutral
Price Target: $161 → $175
Current: $179.71
Upside: -2.62%
AbbVie
Apr 28, 2025
Maintains: Neutral
Price Target: $200 → $204
Current: $220.61
Upside: -7.53%
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Underperform
Price Target: $575 → $547
Current: $563.90
Upside: -3.00%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $112.10
Upside: +12.40%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $24.49
Upside: +38.83%
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $78.56
Upside: +42.57%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $44.12
Upside: +42.79%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $137.37
Upside: +29.58%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $724.54
Upside: +37.60%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $123.65
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $73.76
Upside: -